Literature DB >> 7958066

Enhancing the recognition of tumour associated antigens.

N P Restifo1, B R Minev, A S Taggarse, B J McFarland, M Wang, K R Irvine.   

Abstract

Activated CD8+ T cells (TCD8+) can directly recognize malignant cells because processed fragments of tumour associated antigens (TAA), 8-10 amino acids in length and complexed with MHC class I molecules, are displayed on tumour cell surfaces. Tumour cells have been genetically modified in a variety of ways in efforts to enhance the immune recognition of TAA. An alternative strategy is the expression of TAA in recombinant or synthetic form. This has been made possible by the recent cloning of TAA recognized by TCD8+. In this communication we review recent work in our own laboratory on the expression of TAA as synthetic peptide, by "naked" plasmid DNA injected intramuscularly or transdermally, and by recombinant viruses including vaccinia (rVV), fowlpox (rFV) and adenovirus (rAd). The expression of TAA in recombinant and synthetic forms allows increased control over the quantity, location, and kinetics of TAA presentation and can result in powerful, specific, anti-tumour immune responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958066      PMCID: PMC2763578     

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  64 in total

1.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells.

Authors:  O Rötzschke; K Falk; K Deres; H Schild; M Norda; J Metzger; G Jung; H G Rammensee
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

2.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

Authors:  S L Topalian; D Solomon; S A Rosenberg
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

5.  Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.

Authors:  S J LeGrue; H N Ananthaswamy; W J Simcik
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

6.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

9.  Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance.

Authors:  Y Liu; C A Janeway
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Authors:  Daniel P Webster; Susanna Dunachie; Jenni M Vuola; Tamara Berthoud; Sheila Keating; Stephen M Laidlaw; Samuel J McConkey; Ian Poulton; Laura Andrews; Rikke F Andersen; Philip Bejon; Geoff Butcher; Robert Sinden; Michael A Skinner; Sarah C Gilbert; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.